Globus Medical (GMED)

Healthcare · Medical Devices
$76.43 -0.18% on the day Market cap $11.0B 52-week range $56.50 to $101.40 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
4% a year for 10 years

At a market value of $11.0B, Globus Medical's free cash flow of $589M (fiscal 2025) would need to grow about 4% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 9 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Globus Medical's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price4.1% a year
Free cash flow, last 9 years20.9% a year
Revenue, same period20.1% a year
Price to free cash flow18.6x

Fundamental grade

B

Five factors scored 1 to 9 from GMED's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation6
Profitability6
Growth2
Financial health9
Cash efficiency9

Key numbers

P/E (trailing)18.9x
P/E (forward)17.1x
Price / free cash flow18.6x
EV / EBITDA10.7x
Price / sales3.49x
Price / book2.22x
Revenue growth+5.9%
Operating margin20.3%
Net margin17.0%
Return on equity11.2%
Dividend yield—
Debt / equity0.15x

Results from SEC filings

Fiscal years, from Globus Medical's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$958M$1.0B$1.6B$2.5B$2.9B
Net income$149M$190M$123M$103M$538M
Free cash flow$219M$104M$165M$405M$589M
EPS (diluted)$1.44$1.85$1.07$0.75$3.92
Operating margin17.9%22.3%8.5%6.6%16.3%

Where the revenue comes from

Revenue by products, fiscal 2025.

Musculoskeletal Solutions$2.8B95%
Enabling Technologies$141M5%

Superinvestors who own GMED

From each investor's latest 13F filing (what a 13F shows).

None of the superinvestors we track held GMED in their latest 13F.

Insider buying

Open-market purchases by Globus Medical's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Mar 3, 2026 Gilbert Ray Cisneros, Jr.
0$91.72—
Mar 3, 2026 Gilbert Ray Cisneros, Jr.
0$91.72—

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when GMED trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Globus Medical's stock price imply?

At a market value of $11.0B, Globus Medical would need its free cash flow to grow about 4% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 21% a year.

Are Globus Medical insiders buying the stock?

2 open-market insider purchases of GMED in the last 12 months, from SEC Form 4 filings.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.